Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Lacosamide Approved in Europe for Partial-Onset Epilepsy BRUSSELS, Belgium -- September 3, 2008 -- The European Commission (EC) has approved lacosamide (Vimpat) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. "[Lacosamide] offers new hope for improved seizure control in adult patients with partial onset seizures … [it] should be considered a valuable treatment option for adult patients with partial-onset seizures who need additional seizure control," said trial investigator Elinor Ben-Menachem, Department of Clinical Neuroscience, Göteborg University, Göteborg, Sweden. The approval is based on data from 3 multicentre, randomised, placebo-controlled clinical trials that evaluated the efficacy and safety of lacosamide adjunctive treatment in over 1,300 patients aged 16 years and older with partial-onset seizures that were not adequately controlled with between 1 to 3 concomitant antiepileptic drugs (AED) and with or without additional vagus nerve stimulation. Patients entering these trials were experiencing on average 10 to 15 seizures per month and most patients (84%) were uncontrolled on 2 to 3 AEDs. In clinical trials lacosamide improved seizure control when added to a wide range of first and second generation AEDs. Pooled analysis shows that treatment with lacosamide 200 mg/day and 400 mg/day reduced seizures by half in 34% and 40% of patients with partial-onset seizures, compared with 23% in the placebo group. Lacosamide was generally well tolerated with the most common adverse events (>=10%) reported in these trials including dizziness, headache, nausea, and diplopia. In a long-term study, patients treated with lacosamide achieved sustained reductions in partial-onset seizures. Of 370 patients who took part in this open-label trial, 77% completed at least 12 months of treatment, 61% completed at least 24 months, and 56% completed at least 30 months of treatment. SOURCE: UCB Group E-mail this page to a friend or colleague! To print, use this version